Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
about
Monoclonal antibodies targeting CD38 in hematological malignancies and beyondContribution of Toll-like receptor signaling to germinal center antibody responsesUnraveling the Role of Allo-Antibodies and Transplant InjuryEmerging Therapies for Rheumatoid ArthritisThe pathogenesis, diagnosis and treatment of lupus nephritis.A Systems Biology-Based Investigation into the Pharmacological Mechanisms of Sheng-ma-bie-jia-tang Acting on Systemic Lupus Erythematosus by Multi-Level Data IntegrationB cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.Simultaneous assessment of rotavirus-specific memory B cells and serological memory after B cell depletion therapy with rituximab.Oxidative stress in the pathology and treatment of systemic lupus erythematosusMechanisms of Autoantibody-Induced Pathology.Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition.Comparative effects of n-3, n-6 and n-9 unsaturated fatty acid-rich diet consumption on lupus nephritis, autoantibody production and CD4+ T cell-related gene responses in the autoimmune NZBWF1 mouse.Rationale for B cell targeting in SLEProteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patientsThe proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusImmunology of IgG4-related disease.Haematopoietic stem cell transplantation for autoimmune diseases.Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses.Persistent autoantibody-production by intermediates between short-and long-lived plasma cells in inflamed lymph nodes of experimental epidermolysis bullosa acquisitaHuman CD38hiCD138⁺ plasma cells can be generated in vitro from CD40-activated switched-memory B lymphocytesDifferential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells.Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors.Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis.Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice.γ-Secretase directly sheds the survival receptor BCMA from plasma cellsDisruption of Splenic Lymphoid Tissue and Plasmacytosis in Canine Visceral Leishmaniasis: Changes in Homing and Survival of Plasma Cells.Analyzing pathogenic (double-stranded (ds) DNA-specific) plasma cells via immunofluorescence microscopy.Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunityMacrophages induce differentiation of plasma cells through CXCL10/IP-10Regulation of memory CD4 T-cell pool size and function by natural killer T cells in vivo.Strategies to target long-lived plasma cells for treating hemophilia A inhibitors.CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice.Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor MiceMetabolic Factors that Contribute to Lupus PathogenesisA generalized quantitative antibody homeostasis model: antigen saturation, natural antibodies and a quantitative antibody network.Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?Beyond transitional selection: New roles for BLyS in peripheral toleranceAntinuclear antibodies in rheumatic disease: a proposal for a function-based classification.B cells and antibodies in multiple sclerosis pathogenesis and therapy.Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
P2860
Q26766718-69E0CD5E-3C0E-4503-A111-1AE1DFA7F66EQ26829061-41E05B72-265E-44A0-B1E1-EBDFC66ADFB1Q28069336-A84BA0C9-8571-4325-804D-B33E84922E0AQ28078943-7DB9F3C7-F212-455A-BC24-F3F3BFD15020Q30596968-5B9CE2E1-283D-4527-9CDF-7E79EC05435CQ31021955-ABB2CB34-0A1E-4D9A-99E4-F5D5BBB89BADQ33404838-966291EC-80C6-488B-A4E4-90B303968F3AQ33599297-2C4E143A-9EEC-4912-8E78-EFA22D10C72FQ33715508-995F05A5-7C76-4CC0-8D4D-1C0560BAE1F7Q33740580-00FB2FF3-C29A-41DE-939C-57BDAF286604Q33762211-816DB88B-59DD-4C63-9318-89470100253DQ33778956-22B71684-8ABB-4C9C-A124-52045BC5672AQ33829700-9D9B4913-4ED3-4E9A-BDF8-1A05F8A17325Q34085747-876C742C-77FF-4E25-B680-3FB6046F39EBQ34464260-0CDCDC08-7342-4779-8EF7-00CD14D74172Q34471314-61341120-6B61-4124-90BD-45F9D8E3F25BQ34551863-49D56F0C-8116-4BC9-B3D7-A7D2C1FD8B35Q34647217-0A8E0968-6B1C-483B-A76E-DD5A06377AB5Q35080528-C10E382C-2788-4521-B340-E2A6442EBE6EQ35156154-CADE522F-3FE1-4277-8A23-A79C53EABCDDQ35518822-4C561037-082E-4764-9C44-E3D770C27B3CQ35544326-9B783A0F-6361-4BC2-ACC1-F96B8D79640EQ35736729-35794BC5-4EA5-4ED5-9315-5F7A9CC0EB8DQ35739625-10D05C51-7236-481D-9386-47D74572141DQ35814239-B2CFC7CB-BC08-4DF0-AFFD-3F787FE4037FQ36034698-9C5A428E-282F-4EC0-807F-E8E8D1156A2AQ36202325-D587D884-447F-477F-962E-65FF7D3F3D19Q36245714-3A40EF2F-B600-4A24-9D6E-4C77627D0843Q36278025-EBA8335E-1DBA-4A56-8872-8DA9DACF1AF3Q36342679-4779471F-31F1-4677-B07E-07CFA93FE3B5Q36832899-E117882B-F7D9-4BF4-B5D9-128B974037FEQ36903043-1D464314-501C-4A96-BA87-4C950DDBB934Q37434315-992B84BC-D053-433C-9745-A5F14EA9F301Q37612885-9C280BAF-16A9-45FA-94BC-E1411307E7DFQ37677450-407EB4D2-E147-4F0E-9365-5C943DC801E6Q37912214-B1D47E27-9C8B-4219-BE9D-D4728316A303Q37983058-47E6466F-2CDB-43B7-B10B-A3755202DDA3Q38016455-753022A9-E5BA-432F-8D0A-74C2DBE6CDA7Q38050398-87C6E720-3B3E-4457-8DF1-94CE15F44999Q38068534-B3137EB0-0D45-4DF3-8470-E8C442E359EE
P2860
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
@en
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
@nl
type
label
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
@en
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
@nl
prefLabel
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
@en
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
@nl
P2093
P2860
P356
P1476
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
@en
P2093
Andreas Radbruch
Bimba F Hoyer
Falk Hiepe
Henrik Mei
Thomas Dörner
P2860
P2888
P304
P356
10.1038/NRRHEUM.2011.1
P407
P577
2011-02-01T00:00:00Z